54 metastatic colorectal cancer patients from Schleswig-Holstein in North Germany

Personalized treatment vs standard of care is much debated, especially in clinical practice. Here we investigated whether overall survival differences in metastatic colorectal cancer patients are explained by their tumor mutation profiles or by their treatment differences in real clinical practice.

Type: Other
Archiver: European Genome-Phenome Archive (EGA)

2 Publications

Publications	Citations
Stage IV Colorectal Cancer Patients with High Risk Mutation Profiles Survived 16 Months Longer with Individualized Therapies. Hendricks A, Amallraja A, Meißner T, Forster P, Rosenstiel P, Burmeister G, Schafmayer C, Franke A, Hinz S, Forster M, Williams CB. Cancers (Basel) 12: 2020 E393	3
Detection of Cancer Mutations by Urine Liquid Biopsy as a Potential Tool in the Clinical Management of Bladder Cancer Patients. Ibrahim NK, Eraky A, Eggers J, Steiert TA, Sebens S, Jünemann KP, Hendricks A, Bang C, Stanulla M, Franke A, Hamann C, Röcken C, Arnold N, Hinze L, Forster M. Cancers (Basel) 14: 2022 969	1